Gary Garner, RPh
Hospice and Palliative Medicine · Provo, UTNPI 1811067762
Payments from drug & device makers
What this record shows
22 manufacturers reported payments, led by Novartis at 58.4% of the total. 2025 is the largest year on record at $1,657, more than ten times the $129 reported in 2021.
Across 46 payments — averaging $45.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- Daiichi Sankyo Inc.$174
- Edwards Lifesciences$129
- Johnson & Johnson$68
- AstraZeneca$65
- Array Biopharma Inc$41
- plus $396 from 16 others
What the payments were for
- Food & beverage$90343%
- Other$1,19657%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 14 | $1,227 |
| Daiichi Sankyo Inc. | 7 | $174 |
| Edwards Lifesciences | 1 | $129 |
| Johnson & Johnson | 2 | $68 |
| AstraZeneca | 3 | $65 |
| Array Biopharma Inc | 2 | $41 |
| Merck | 2 | $40 |
| Beone Medicines USA, Inc. | 1 | $35 |
| Tactile Systems Technology Inc | 1 | $33 |
| Immunocore Limited | 1 | $32 |
| Pfizer | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Bayer | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $24 |
| Beigene USA, Inc. | 1 | $23 |
| Tersera Therapeutics LLC | 1 | $21 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Genmab U.S., Inc. | 1 | $18 |
| Seagen Inc. | 1 | $18 |
| Amgen | 1 | $17 |
| Blueprint Medicines Corporation | 1 | $16 |
How this compares
Too few hospice and palliative medicine providers in Utahto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone Hcl | 131 | $2,500 |
| Morphine Sulfate ErMorphine Sulfate | 72 | $1,597 |
| Fentanyl | 16 | $1,510 |
| Lansoprazole | 20 | $1,394 |
| Pregabalin | 18 | $615 |
| Hydromorphone Hcl | 30 | $442 |
| Gabapentin | 34 | $382 |
| Prochlorperazine Maleate | 19 | $347 |
| Methylphenidate Hcl | 13 | $323 |
| Trazodone Hcl | 13 | $311 |
| Lorazepam | 23 | $261 |
| Duloxetine Hcl | 13 | $258 |
| Escitalopram Oxalate | 17 | $247 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 15 | $207 |
| Dexamethasone | 25 | $176 |
Paid to pharmacies, not to this prescriber.
Other hospice and palliative medicine in Provo
- Jeffrey BrobergProvo$761
- Matthew SchellenbergMurray$2K
- Jeffrey JacksonWest Jordan$2K
- Jamie RebmanMurray$305
- Anna BeckSalt Lake City$165
- Cari LowSalt Lake City$125
- Jane MacphersonMurray$39
- Kathleen IrbySalt Lake City$30
- Scott FahrnerSalt Lake City$28
- Zachary EreksonSt George$25
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.